CannabisNewsBreaks

ThursdaySep 15, 2022 1:38 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Hypertension Treatment Program Stands Distinct

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently provided information to its stakeholders to help them conveniently research and understand different non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies. The information includes a discussion of underlying logic-based evaluations that offer a realistic framework of expectations that investors can use in their analysis. “One of the logic-based evaluations considers the stage at which a company’s drug development program has reached. According to the U.S. Food and Drug Administration (‘FDA’), there are five steps to the drug development process: discovery and development, preclinical research, clinical research, FDA drug review, and,…

Continue Reading

WednesdaySep 14, 2022 10:52 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Closes $6M Private Placement Agreement

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, has closed on a private placement agreement with two healthcare-focused institutional investors. The agreement consisted of the issue and sale of 691,245 of INM common shares prices at $8.68 per share (or prefunded warrant in lieu thereof), totaling approximately $6 million. According to the announcement, INM also issued unregistered preferred investment options allowing the investors to purchase up to 1,382,490 additional common shares. The company observed that the unregistered investment options issued are exercisable upon issuance at an exercise price of $8.44 per share with an…

Continue Reading

TuesdaySep 13, 2022 12:42 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Recognized for Strategic M&A Objectives at Benzinga Cannabis Capital Conference

Flora (NASDAQ: FLGC) is a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands. The company today announced its receipt of the Best M&A Deal award at Benzinga’s 2022 Cannabis Capital Conference in Chicago. “We are honored to receive the award for Best M&A Deal at the Benzinga Cannabis Capital Conference, which recognizes our strategic M&A objectives including acquiring products, expertise, expanding distribution, and customers,” said Luis Merchan, chairman and CEO of Flora. To view the full press release, visit https://cnw.fm/vKY3n About Flora Growth Corp. Flora is building a connected, design-led collective of plant-based wellness and lifestyle…

Continue Reading

MondaySep 12, 2022 12:29 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Enters into $6M Securities Purchase Agreement

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, has announced a private placement agreement with two healthcare-focused institutional investors. The agreement calls for the issuance and sale of 691,245 of INM common shares; the shares will be sold at a purchase price of $8.68 per share in a private placement priced according to Nasdaq guidelines. According to the announcement, InMed will also issue unregistered preferred investment options that will allow investors in the offering to purchase more than 1.3 million common shares. The company noted that it anticipates gross proceeds from the placement,…

Continue Reading

WednesdaySep 07, 2022 11:34 am

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Subsidiary Announces Acquisition of Emerging Hemp Flower Market Brand

Flora Growth (NASDAQ: FLGC), an all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, announced that its wholly owned subsidiary, Just Brands LLC, has acquired substantially all of the assets related to the No Cap Hemp Co. brand. The company anticipates that the acquisition of this emerging brand in the hemp flower market will diversify its brand portfolio and product offerings as well as create an opportunity to expand Flora’s distribution foothold in the United States by providing a unique collection of products with strong revenue growth potential. According to the announcement, the acquisition will offer Flora an…

Continue Reading

FridaySep 02, 2022 11:01 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced an addition to its board of directors; the company named industry veteran Catherine Turkel, PharmD, PhD, as the newest member of its board. Turkel brings more than two decades of experience as an executive-level leader in both start-up and mid-size pharma/biotech companies. As founder and CEO of Nezee Therapeutics, she gained critical expertise and insight in the space; she also served as president and head of research and development Novus Therapeutics, which was later renamed Eledon Pharmaceuticals Inc. (NASDAQ: ELDN). Currently she serves as an independent board director…

Continue Reading

WednesdayAug 31, 2022 2:26 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces New Patent in Mexico

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is continuing to accumulate international patents; most recently the company received its 27th patent granted worldwide. Part of Lexaria’s third patent family — Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents, from which patents have already been granted from Australia, India and Japan — the newest patent comes from Mexico and applies to range of active ingredients including non-psychoactive cannabinoids and NSAIDs. The announcement noted that types of products covered by the patent include specific pharmaceutical product formats along with an array of ready-to-drink consumer retail beverage products. According to the announcement,…

Continue Reading

MondayAug 22, 2022 1:21 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands to Gain Substantial Revenue Through Licensing of DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced that Japanese Licensee, Premier Wellness Science Co. Ltd., officially launched the first generation of its new cannabidiol (“CBD”) products under the brand, “Ko.” “The exclusive rights between Premier and Lexaria are subject to two previously issued licenses for using DehydraTECH technology in Japan for non-pharmaceutical cannabinoid products… Under the terms of the license agreement with Lexaria, Premier purchased rights to the company’s DehydraTECH technology for use in the non-pharmaceutical market for CBD and hemp ingredients in oral liquid and non-liquid product form, including topical, hair care, lip care, and cosmetics,” a recent article…

Continue Reading

WednesdayAug 17, 2022 2:41 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH Capable of Delivering APIs More Efficiently by Overcoming Food Effect

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced the allowance of a new patent in Japan, the fourth to be granted in that country and the 26th worldwide. “Entitled Lipophilic Active Agent Infused Compositions with Reduced Food Effect, this is the first patent issued from Lexaria’s seventh patent family and refers to tetrahydrocannabinol (‘THC’). The new patent acknowledges DehydraTECH(TM)’s ability to deliver active pharmaceutical ingredients (‘APIs’) more efficiently, in a process known as absorption, regardless of the presence of food in the gastrointestinal system. Ordinarily, food impacts drug absorption by physically interacting with drugs, altering the pH, stimulating bile flow, slowing…

Continue Reading

TuesdayAug 16, 2022 11:10 am

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Releases Financial Results for H1 2022

Flora Growth (NASDAQ: FLGC), a manufacturer and distributor of global cannabis products and brands, is reporting its financial and corporate results for the six months ending June 30, 2022. Highlights of the report include revenue for the company increasing 604% from the same period last year, reaching ~$15 million while gross profit for the company increased to ~$7 million, an increase of 547%. In the report, the company reaffirmed its 2022 revenue guidance of $35 million to $45 million, which represents an increase in projected revenue of between 300% to 400%. “In the first half of 2022, Flora delivered on…

Continue Reading